The aim of this study was to evaluate the effectiveness of a progressive program for the treatment of erectile dysfunction in patients with cardiovascular disease in whom sildenafil citrate (Viagra) was not an option. The study population included 106 patients selected from 267 with cardiovascular disease. The intracavernous injection program consisted of three protocols of increasingly complex combinations of vasoactive drugs, papaverine, phentolamine, prostaglandin E1 and atropine sulfate. Patients who failed the first protocol were switched to the second, and those who failed the second were switched to the third. A positive response was defined as an erection sufficient for vaginal penetration. A positive response was achieved on protocol I in 61 of the 106 patients (57.5%); protocol II in 32 of the remaining 45 patients (71.1%); and protocol III in seven of the remaining 13 patients (53.8%); the total success rate was 94.3%. These 100 patients were included in the 1-year follow-up, and 90 reported successful coitus at the end of that period: 79 patients (87.8%) with intracavernous injection and 11 (12.2%) without injection. The remaining 10 patients (10%) dropped out of the program, seven (7.0%) for health or marital reasons and three (3.0%) because of treatment failure. We conclude that a progressive program of intracavernous injections of vasoactive drugs may be a good alternative for the treatment of erectile dysfunction in patients with cardiovascular disease.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Conti CR, Pepine CJ, Sweeney M. . Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999 83: 29C–34C.
Goldstein I et al . Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998 338: 1397–1403.
McMahon CG, Samali R, Johnson H. . Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000 164: 1192–1196.
Meuleman B et al . A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. Br J Urology 2001 87: 75–81.
Kloner RA, Jarow JP. . Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999 83: 576–580.
Zusman RM, Morales A, Glasser DB, Osterloh IH. . Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999 83: 35–43c.
Herrmann HC, Change G, Klugherz BD, Mahoney PD. . Hemodynamic effects of sildenafil in men with severe coronary artery disease. New Engl J Med 2000 342: 1622–1626.
Mydlo JH, Volpe MA, Macchia RJ. . Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000 38: 30–34.
Moreira SG et al . Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000 56: 474–476.
Cheitlin MD et al . Use of sildenafil (Viagra) in patients with cardiovascular disease. Circ J Am Health Assoc 1999 99: 166–177.
Tzivoni D, Klein J, Hisdai D, Roth A. . The Israel Heart Society Expert Consensus document: The cardiac patient and sexual activity in the era of sildenafil (Viagra). Isr Med Assoc J (IMAJ) 2000 2: 63–65.
Rosen RC et al . The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997 49: 822–830.
Cappelleri JC et al . Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999 54: 346–351.
Bland M. . Introduction to Medical Statistics Oxford University Press: Oxford 1989 20–104.
McMahon CG, Samali R, Johnson H. . Treatment of intracorporeal injection nonresponders with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999 162: 1992–1997.
Shabsigh R et al . Intracavernous alprostadil alfadex (Edem/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000 55: 477–480.
Hatzichristou DG et al . Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 y. J Urol 2000 164: 1197–1200.
Gasser TC et al . Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence. J Urol 1987 137: 678–680.
Bechara A et al . Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol 1997 157: 2132–2134.
Levine SB et al . Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989 141: 54–58.
Floth A, Schremer P. . Intracavernous injections of prostaglandin E1 in combination with papaverine-enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E. J Urol 1991 145: 56–59.
Purvis K, Edgetveit I, Christiansen E. . Intracavernosal therapy for erectile failure—impact of treatment and reasons for drop-out and dissatisfaction. Int J Impot Res 1999 11: 287–299.
Godschalk M, Cheorghiu D, Katz PG, Mulligan T. . Alkalization does not alleviate penile pain induced intracavernous injection of prostaglandin E1 J Urol 1996 156: 999–1000.
Montorsi F et al . Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J Urol 1993 149: 1291–1295.
Sogari PR, Teloken C, Souto CAV. . Atropine role in the pharmacological erection test: study of 228 patients. J Urol 1997 158: 1760–1763.
Brock G, Lei Mai Tu, Linet O. . Return of spontaneous erection during long-term cavernosal alprostadil (Caverject) treatment. Urology 2001 57: 536–541.
Mantam P et al . Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy. J Urol 2001 165: 830–833.
About this article
Cite this article
Israilov, S., Niv, E., Livne, P. et al. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Int J Impot Res 14, 38–43 (2002). https://doi.org/10.1038/sj.ijir.3900812
This article is cited by
Laparoscopic treatment of pudendal nerve and artery entrapment improves erectile dysfunction in healthy young males
International Journal of Impotence Research (2021)
A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1
International Journal of Impotence Research (2005)